Osteoporosis Drugs Market

Osteoporosis is a progressive, skeletal disease, leading to fragile and abnormally porous bones. It is characterized by decrease in bone density, strength, and micro-architectural deterioration of bone tissue resulting in thinning or weakening of bones with an increased propensity of fractures. Primary and secondary osteoporosis are the major types of osteoporosis. Some of the factors leading to osteoporosis are genetic factor, aging, lack of calcium and vitamin D, smoking, lack of exercise, low body weight, excessive alcohol consumption, history of rheumatoid arthritis, menopause, and certain medication. Osteoporosis can be diagnosed using X-ray and can be confirmed by bone density scan. Dual energy X-ray absorptiometry (DEXA) is the common bone density test used to measure the density of bones. Treatment for osteoporosis begins with a change in lifestyle and diet. It can be prevented and treated with the help of calcium and vitamin D supplements, exercise, and osteoporosis medications. Prevalence of osteoporosis is high among people aged 60 years and above. Moreover, estrogen plays a vital role in regulating the bone growth process in women. Post menopause, bone breakdown outpaces the building of new bone matter. The rate of bone loss in women increases after menopause, leading to the threat of developing osteoporosis.

North America is the largest market for osteoporosis drugs due to increasing geriatric population, growing investment in R&D for the discovery of innovative drugs, and rising prevalence of lifestyle-associated diseases in the region. Asia-Pacific is expected to exhibit high growth rates over the following five years in the global osteoporosis drugs market. China and India are expected to be the fastest-growing markets for osteoporosis drugs in Asia Pacific. Some of the key driving forces for the osteoporosis drugs market in emerging countries are rising geriatric population, a large pool of patients, changing lifestyles, increasing healthcare expenditure, and growing awareness about osteoporosis care in these regions.

Rising geriatric population, changing lifestyle impinging bone health, and increasing prevalence of osteoporosis in post-menopausal women are some of the factors driving the growth of the global osteoporosis drugs market. In addition, increasing awareness about osteoporosis care and growing investments in R&D for the discovery of innovative drugs are also fueling the growth of the market. On the other hand, side effects and complications such as irritable bowel syndrome, nausea, and ulcers in stomach or esophagus, associated with osteoporosis drugs and patent expiration of osteoporosis drugs are inhibiting growth of the global osteoporosis drugs market.

This report provides in-depth analysis and estimation of the osteoporosis drugs market for 2015– 2022, considering 2014 as the base year for calculation. Moreover, data pertaining to current market dynamics, including market drivers, restraints, trends, and recent developments, has been provided in the report.

Key segments covered in this report are:

• By drugs type
  • Bisphosphonates
  • Parathyroid Hormone Therapy Drugs
  • Calcitonin
  • Selective Estrogen Receptors Modulators (SERMs)
  • RANK Ligand Inhibitors

Key geographies evaluated in this report are:

• North America
  • U.S.

• Europe
  • France, Germany, and the UK 
  • Rest of Europe

• APAC
  • China
  • India
  • Japan
  • Rest of Asia Pacific

Key features of this report

• Drivers, restraints, and challenges shaping the osteoporosis drugs market dynamics
• Latest innovations and key events in the market
• Analysis of business strategies of the top players in the market
• Osteoporosis drugs market estimates and forecasts

Companies covered in Osteoporosis Drugs Market

Top companies profiled in this report are:

• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd.
• Merck & Co, Inc.
• Novartis AG
• Amgen, Inc.
• Novo Nordisk A/S
• Actavis plc
• Pfizer, Inc.
• GlaxoSmithKline plc
• Teva Pharmaceutical Industries Ltd
• Other